Publications and communications of Anna Lechanteur

Ahmed, A. A., Schimmel, K. J. M., Tubic-Grozdanis, M., Tuleu, C., Smith, J., Soulairol, I., Dadkhah, A., Paulson, M., Lechanteur, A., Carrez, L., Schnor, T., Lagarce, F., Le Brun, P. P. H., & Crauste-Manciet, S. (25 December 2025). Expert opinion on extrusion-based pharmaceutical 3D printing from the European Society of Hospital Pharmaceutical Technology (GERPAC). International Journal of Pharmaceutics, 686, 126321. doi:10.1016/j.ijpharm.2025.126321

Dowek, A., Seidakhanova, A., Bourcy, Q., Jennotte, O., Evrard, B., Crunenberg, R., Ziemons, E., Do, B., Annereau, M., Rieutord, A., & Lechanteur, A. (2025). Ensuring quality control in HME, a quantitative analysis of hydrocortisone filament using a portable Raman spectrometer. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 126968. doi:10.1016/j.saa.2025.126968

Gresse, E., Gemine, T., Renauld, L., Evrard, B., Lumay, G., & Lechanteur, A. (15 July 2025). Manufacturing softpellets using triboelectric agglomeration of fine powders on a vibrated inclined plane: Method and application to dry powder inhalion. Powder Technology, 460, 121070. doi:10.1016/j.powtec.2025.121070

Bya, L.-A., Bottero, B., Coeurderoi, A., Dinh, T. N., Sacre, P.-Y., Ziemons, E., Cataldo, D., Piel, G., Evrard, B., & Lechanteur, A. (10 June 2025). Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying. International Journal of Pharmaceutics, 678, 125696. doi:10.1016/j.ijpharm.2025.125696

Bya, L.-A., Dinh, T. N., Penoy, N., Sacre, P.-Y., Bottero, B., Cataldo, D., Piel, G., Evrard, B., & Lechanteur, A. (31 March 2025). OPTIMIZING LIPOSOME PRESERVATION THROUGH SPRAY-DRYING: ATOMIZATION PARAMETER ADJUSTMENT AND ANALYSIS OF LIPOSOME COMPOSITION AND LIPOSOME-TO-CARBOHYDRATE RATIOS VIA EXPERIMENTAL DESIGN [Paper presentation]. 22nd FORUM OF PHARMACEUTICAL SCIENCES, La Roche-en-Ardenne, Belgium.

Santos Gomes, B. F., Bya, L.-A., Koch, N., Cabral-Marques, H., Evrard, B., & Lechanteur, A. (17 January 2025). Cannabidiol and Hydroxypropyl-β-Cyclodextrin for the Development of Deflated Spherical-Shaped Inhalable Powder. AAPS Journal, 27 (1), 30. doi:10.1208/s12248-025-01015-y

Gresse, E., Gemine, T., Renauld, L., Lumay, G., Evrard, B., & Lechanteur, A. (2025). SoftpelletsProduction by Self-Agglomeration Process [Poster presentation]. 5th European Conference on Pharmaceutics, Porto, Portugal.

Koch, N., Bourcy, Q., Jennotte, O., Chiap, P., Lechanteur, A., Cardot, J.-M., & Evrard, B. (2025). Selection of In Vivo Relevant Dissolution Test Parameters for the Development of Cannabidiol Formulations with Enhanced Oral Bioavailability. Pharmaceutics. doi:10.3390/pharmaceutics17010079

Nyamba, I., Wanko Nembot, A. M., Sombié B Charles, Zimé - Diawara Hermine, Yaméogo B.G Josias, Lechanteur, A., Damblon, C., Semdé Rasmané, & Evrard, B. (20 July 2024). Evaluation of the application of polyethylene glycol 8000 as a plasticizer for the development of solid dispersions based on ellagic acid and Eudragit® EPO using hot melt extrusion. Journal Africain de Technologie Pharmaceutique et Biopharmacie, Vol.3 Nº1 2024. doi:10.57220/jatpb.v3i1.179

Nyamba, I., Charles B. SOMBIE, Lechanteur, A., Rasmané SEMDE, & Evrard, B. (2024). Potential of Native Cyclodextrins and L-Lysine for Enhancing Ellagic Acid Aqueous Solubility. International Journal of Drug Delivery Technology. doi:10.25258/ijddt.14.2.48

Koch, N., Jennotte, O., Bourcy, Q., Lechanteur, A., DEVILLE, M., Charlier, C., CHIAP, P., Cardot, J. M., & Evrard, B. (27 April 2024). Evaluation of amorphous and lipid-based formulation strategies to increase the in vivo cannabidiol bioavailability in piglets. International Journal of Pharmaceutics, 657, 124173. doi:10.1016/j.ijpharm.2024.124173

Bya, L.-A., Coeurderoi, A., Dinh, T. N., Bottero, B., Sacre, P.-Y., Ziemons, E., Cataldo, D., Piel, G., Lechanteur, A., & Evrard, B. (17 April 2024). Assessment of the Effects of Drying Methods on Powder Properties: A Comparative Study of Spray Drying from Solution and Suspension [Poster presentation]. 9th Workshop on Pulmonary Drug Delivery, Dublin, Ireland.

Gresse, E., Rousseau, J., Akdim, M., Du Bois, A., Lechanteur, A., & Evrard, B. (2024). Enhancement of inhaled micronized powder flow properties for accurate capsules filling. Powder Technology, (119576). doi:10.1016/j.powtec.2024.119576

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Maquoi, E., Pendeville-Samain, H., Evrard, B., Jérôme, C., Chain, J. L., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (2024). Poly(N-methyl‐N‐vinylacetamide): a strong alternative to PEG for lipid‐based nanocarriers delivering siRNA. Advanced Healthcare Materials, 2302712. doi:10.1002/adhm.202302712

Cerveto, T., Denis, L., Stoops, M., Lechanteur, A., Jérôme, C., Leenhardt, J., Flynn, S., Goyanes, A., Mazet, R., Annereau, M., & Choisnard, L. (2024). The promising role of semi-solid extrusion technology in custom drug formulation for pediatric medicine. International Journal of Bioprinting, 10 (6), 38 - 66. doi:10.36922/ijb.4063

Koch, N., Jennotte, O., Lechanteur, A., DEVILLE, M., Charlier, C., Cardot Jean-Michel, CHIAP, P., & Evrard, B. (2024). An Intravenous Pharmacokinetic Study of Cannabidiol Solutions in Piglets through the Application of a Validated Ultra-High-Pressure Liquid Chromatography Coupled to Tandem Mass Spectrometry Method for the Simultaneous Quantification of CBD and Its Carboxylated Metabolite in Plasma. Pharmaceutics. doi:10.3390/pharmaceutics16010140

Jennotte, O., Koch, N., Lechanteur, A., Rosoux, F., Emmerechts, C., Beeckman, E., & Evrard, B. (05 November 2023). Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule. International Journal of Pharmaceutics, 646, 123506. doi:10.1016/j.ijpharm.2023.123506

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (September 2023). Formulation and quality consideration of cannabidiol printed forms produced by fused-deposition modeling. Journal of Drug Delivery Science and Technology, 87, 104837. doi:10.1016/j.jddst.2023.104837

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Laloy, J., Pendeville-Samain, H., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (02 August 2023). Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. Journal of Controlled Release, 361, 87 - 101. doi:10.1016/j.jconrel.2023.07.031

Parulski, C., Bya, L.-A., Goebel, J., Servais, A.-C., Lechanteur, A., & Evrard, B. (13 June 2023). Development of 3D printed mini-waffle shapes containing hydrocortisone for children's personalized medicine. International Journal of Pharmaceutics, 642 (123131). doi:10.1016/j.ijpharm.2023.123131

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597

Nyamba, I., Jennotte, O., Charles B Sombié, Lechanteur, A., Sacre, P.-Y., Abdoulaye Djandé, Rasmane Semde, & Evrard, B. (2023). Preformulation study for the selection of a suitable polymer for the development of ellagic acid-based solid dispersion using hot-melt extrusion. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2023.123088

Ayyoubi, S., Van Kampen, E., Kocabas, L. I., Parulski, C., Lechanteur, A., Evrard, B., De Jager, K., Muller, E., Wilms, E. W., Meulenhoff, P. W. C., & Ruijgrok, E. J. (December 2022). 3D printed, personalized sustained release cortisol for patients with adrenal insufficiency. International Journal of Pharmaceutics, 630, 122466. doi:10.1016/j.ijpharm.2022.122466

Nyamba, I., Sombié, C., Lechanteur, A., Semdé, R., & Evrard, B. (02 February 2022). Complexation with cyclodextrins and solid dispersions formation as physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid [Paper presentation]. CIRM Day 2022, Liège, Belgium.

Ilangala Booka, A., Lechanteur, A., Fillet, M., & Piel, G. (2021). Therapeutic peptides for chemotherapy: trends and challenges for advanced delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2021.07.010

Lechanteur, A., & Evrard, B. (2020). Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review. Pharmaceutics. doi:10.3390/pharmaceutics12010055

Schmitt, C., Lechanteur, A., Cossais, F., Bellefroid, C., Arnold, P., Lucius, R., Held-Feindt, J., Piel, G., & Hattermann, K. (2020). Liposomal Encapsulated Curcumin Effectively Attenuates Neuroinflammatory and Reactive Astrogliosis Reactions in Glia Cells and Organotypic Brain Slices. International Journal of Nanomedicine, 15, 3649—3667. doi:10.2147/IJN.S245300

Ilangala Booka, A., COBRAIVILLE, G., EVRARD, A., Sonveaux, Lechanteur, A., Piel, G., & Fillet, M. (11 December 2019). LC-UV as tool for nanovectorized anticancer peptide quality control: evaluation of encapsulation efficiency [Poster presentation]. 2nd Edition of CIRM day, Liege, Belgium.

Sounouvou, A. G. H. T., Toukourou, H., Lechanteur, A., Piel, G., Quetin-Leclercq, J., Gbaguidi, F., & Evrard, B. (11 December 2019). Development of dermatological dosage forms based on essential oils for the treatment of common skin infections [Paper presentation]. 2nd CIRM day, Liege, Belgium.

Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., & Piel, G. (August 2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape [Paper presentation]. 12th International Conference and Workshop on Biological barriers, Saarbruck, Germany.

Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., & Piel, G. (2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape. Nanomaterials, 8 (5). doi:10.3390/nano8050270

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (07 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. SF Nano Annual Meeting 2017, Bordeaux, France.

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (05 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 4th SF Nano Annual Meeting, Bordeaux, France.

Sgorla, D., Lechanteur, A., Almeida, A., Sousa, F., Melo, E., Bunhak, É., Mainardes, R., Khalil, N., Cavalcanti, O., & Sarmento, B. (2017). Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opinion on Drug Delivery. doi:10.1080/17425247.2018.1420050

Lechanteur, A., das Neves, J., & Sarmento, B. (2017). The role of mucus in cell-based models used to screen mucosal drug delivery. Advanced Drug Delivery Reviews. doi:10.1016/j.addr.2017.07.019

Lechanteur, A., Almeida, A., & Sarmento, B. (2017). Elucidation of the impact of cell culture conditions of Caco-2 cell monolayer on barrier integrity and intestinal permeability. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2017.06.013

Lechanteur, A., Furst Tania, Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (25 April 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 1st SPLC-Controlled Release Society, Santiago de Compostela, Spain.

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (2015). Anti-E6/E7/MCL-1 pegylated lipoplexes for a vaginal treatment of cervical cancer [Paper presentation]. 1st European Conference on Pharmaceutics: Drug Delivery, Reims, France.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 November 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 2014 AAPS Annual Meeting and Exposition, San Diego, United States.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (20 October 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 3rd NanoFar Autumn School, Louvain, Belgium.

Lechanteur, A., Furst, T., Kanber, E., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (04 October 2014). Development and optimization of pegylated lipoplexes for vaginal application [Paper presentation]. SFNano Workshop 2014, Porto, Portugal.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (27 August 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES TO BE INCORPORATED INTO MUCOADHESIVE HEC-SPONGES [Poster presentation]. Translational Nanomedicine, International Meeting, Angers, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (19 May 2014). ASSOCIATION OF LIPOSOMES AND siRNA FOR A LOCAL TREATMENT OF CERVICAL CANCER [Poster presentation]. GIGA-Cancer Day 2014.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 April 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI E6/E7 ONCOPROTEINS FOR THE TREATMENT OF HPV CANCERS [Poster presentation]. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbonne, Portugal.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (16 February 2014). Development of PEG-coated lipoplexes with siRNA anti-E6/E7 oncoproteins to be incorporated into mucoadhesive HEC-sponges for the treatment of HPV cancers [Poster presentation]. 10th International Conference and Workshop on Biological Barriers, Saarbrucken, Germany.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (16 February 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. 10th International conference and workshop on Biological Barriers.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (27 January 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. GIGA-Day 2014.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (05 December 2013). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. Séminaire des chercheurs du Télévie 2014.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (03 December 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. 28ième Journées Scientifiques du GTRV, Angers, France.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (02 December 2013). Development of peggylated lipoplexes with siRNA anti-E6/E7 oncoproteins for the treatment og cancers induced by HPV [Poster presentation]. GTRV, Orléans, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (17 October 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. Dix-septième forum des sciences pharmaceutiques.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Poster presentation]. Cancer GIGA-Day 2013, liège, Belgium.

Lechanteur, A., Evrard, B., Delvenne, P., RONCARATI, P., Hubert, P., & Piel, G. (November 2012). Development and optimization of lipoplex vectors for an antisens therapeutic approach in the context of HPV induced lesions [Poster presentation]. Ecole doctorale en cancérologie expérimentale, liège, Belgium.

Furst, T., Lechanteur, A., Evrard, B., Delvenne, P., Hubert, P., Piette, M., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar 1st Autumn School, Angers, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar Automn School, Angers, France.